Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Craig Barbarosh, a director at Evolent Health, Inc. (NYSE:EVH), recently purchased 2,000 shares of the company’s Class A common stock, according to a filing with the Securities and Exchange Commission. The transaction, which took place on March 6, 2025, was executed at a price of $8.81 per share, totaling $17,620. The purchase comes as the stock trades near its 52-week low of $8.35, having declined over 70% in the past year. InvestingPro analysis indicates the stock is currently undervalued, with management actively buying back shares. Following this purchase, Barbarosh holds 31,956 shares, which includes previously granted restricted stock units. While 8 analysts have recently revised their earnings expectations downward, they maintain an optimistic outlook, with InvestingPro data showing net income growth expected this year. For deeper insights into EVH’s valuation and growth prospects, access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, Evolent Health reported fourth-quarter results that did not meet analyst expectations, with adjusted earnings per share at -$0.02, missing the consensus estimate of $0.07. Revenue for the quarter was $646.5 million, below the expected $652.2 million but still marking a 16.3% year-over-year increase. For the full year 2024, Evolent’s revenue reached $2.55 billion, a 30.1% increase over 2023. However, the company’s revenue forecast for 2025, between $2.06 billion and $2.11 billion, fell short of the $2.42 billion analysts anticipated.
In response to these developments, Citizens JMP raised its price target for Evolent Health to $13, maintaining a Market Outperform rating, expressing confidence in the management’s strategy. Meanwhile, Piper Sandler adjusted its price target to $16 from $17, maintaining an Overweight rating, and noted the company’s strong customer retention and value proposition. Evolent Health has also signed contract amendments expected to improve net income and adjusted EBITDA by $115 million annually for 2025. The company expects first-quarter 2025 revenue to be between $440 million and $470 million, with adjusted EBITDA ranging from $31 million to $37 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.